Tag:
migraine
Latest Headlines
Latest Headlines
UPDATED: FDA stiff-arms Map's app for migraine therapy Levadex
Hours after the markets closed last night, Map Pharmaceuticals put out the word that the FDA had stiff-armed its application for the inhalable migraine therapy Levadex.
Impax licenses U.S. rights to AstraZeneca migraine drug, variations likely
Impax Pharmaceuticals is paying AstraZeneca ( $AZN ) $130 million so it can license U.S. commercial rights for three versions of the migraine drug Zomig. Their agreement also allows for new variations
Arteaus launches with $18M from Atlas, OrbiMed
Atlas Venture and OrbiMed Advisors have provided $18 million to bankroll Arteaus Therapeutics, a Cambridge, MA-based developer that came out of stealth mode today. Arteaus, headed by Atlas' David
Merck kills PhIII migraine drug program
Merck's ( $MRK ) headaches in developing migraine drugs continue. The drug giant revealed today that it has kicked to the curb its late-stage drug telcagepant , a once-touted experimental drug for acute
Three genetic perps fingered for migraine risk
Researchers at Brigham and Women's Hospital have identified three genes associated with greater risk for migraines, a debilitating condition that goes way beyond a simple headache. Migraine sufferers
Merck scraps one migraine drug, pushes another
Spooked by signs of elevated liver enzyme levels, Merck announced today that it is dumping its development program for the acute migraine therapy MK-3207. But it touted promising results for a
NuPathe reports positive results for migraine patch
NuPathe announced positive results from a key late-stage study of Zelrix, a transdermal patch designed for the treatment of acute migraine. The multi-center trial involved 530 adults. Data from the
MAP touts inhalable migraine med data
Shares of MAP Pharmaceuticals soared this morning on news that the company's inhalable migraine therapy Levadex (MAP0004) met all four primary endpoints in a Phase III study. Levadex achieved
Allergan says data supports Botox for migraines
Shares of Allergan shot up 13 percent on the news that Botox worked as a therapy for chronic migraines in a late-stage trial. And based on its analysis from two studies, Allergan says it will go to
